New Indication For GABA And Its Metabolism In Pre-Eclampsia

Tech ID: 29754 / UC Case 2016-401-0


UCLA researchers in the Department of Obstetrics and Gynecology have developed a novel biomarker for pre-eclampsia diagnosis.


Pregnant women with pre-eclampsia have twice the risk of stillbirth compared to unaffected women. It affects nearly 2%-8% pregnancies and is one of the leading pregnancy-associated disorders. It results in hypertension, kidney dysfunction, and, in rare cases, can lead to seizures. Furthermore, the etiology of the disease is completely unknown. Currently, there are no therapeutics and diagnosis is based on symptoms.


UCLA researchers in the Department of Obstetrics and Gynecology have identified a novel therapeutic target for pre-eclampsia patients. Their results suggest that a key neurotransmitter is expressed in endothelial cells and is misregulated in pre-eclampsia patients. They have developed a novel serum biomarker assay that was tested on pre-eclampsia patients. The biomarker assay is the first diagnostic tool for pre-eclampsia patients.


  • Assay for diagnosis of pre-eclampsia 
  • Therapeutic target for pre-eclampsia


  • Easy and straightforward assay 
  • Accurate diagnosis

State Of Development

  • Mechanism investigated in patient derived cells 
  • Biomarker assay developed and tested with patient derived serum

Related Materials


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Sen, Suvajit

Other Information


Pregnancy, pre-eclampsia, pre-mature birth, endothelial cells, seizures, biomarker

Categorized As